Health Care • Biotechnology: Pharmaceutical Preparations
$21.35 ▲ +0.21
(+0.99%)
MKT CAP: $7.44B • VOL: 4.40M
52W L $11 52W H $22
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$18
MEDIAN
$24
MEAN
$24
HIGH
$29
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE AMRX TAPE
AMRX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $25.83 | $24.55 | 2025-02-14 | $19.43 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $26.90 | $25.19 | 2025-02-06 | $20.07 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $24.34 | $23.49 | 2025-01-29 | $20.50 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $21.78 | — | 2025-01-17 | $20.92 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $18.79 | $20.28 | 2025-01-09 | $19.00 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $25.41 | $22.20 | 2024-12-18 | $18.57 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $20.71 | $21.56 | 2024-12-04 | $19.86 | -4.3% | 48% | C |